New combo targets Gene-Mutated breast cancer after first treatment fails
NCT ID NCT05392608
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding alpelisib to continued fulvestrant can help people with advanced, hormone-receptor-positive, HER2-negative breast cancer that has a PIK3CA mutation. Participants have already seen their cancer progress while on fulvestrant. The study aims to see how long the combination can control the cancer. 130 adults are enrolled across multiple centers in the Netherlands.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Alpelisib (Piqray) and fulvestrant (Faslodex)
What this could lead to
If successful, this could offer a new treatment option for people with a specific genetic mutation in advanced breast cancer, potentially delaying further disease progression.
What could go wrong
This is an early-phase, single-arm study with no comparison group, so results may not be definitive. Side effects from alpelisib can be significant, and the benefit may be limited to a subset of patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASM, BREAST are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Admiraal de Ruyter Ziekenhuis
Goes, Netherlands
-
Amphia
Breda, Netherlands
-
Amsterdam UMC
Amsterdam, Netherlands
-
Antoni van Leeuwenhoek
Amsterdam, Netherlands
-
Canisius Wilhelmina Ziekenhuis
Nijmegen, Netherlands
-
Deventer ziekenhuis
Deventer, Netherlands
-
Elisabeth-TweeSteden Ziekenhuis
Tilburg, Netherlands
-
Franciscus Gasthuis & Vlietland
Schiedam, Netherlands
-
Gelre Ziekenhuizen
Apeldoorn, Netherlands
-
HagaZiekenhuis
The Hague, Netherlands
-
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, Netherlands
-
Maasstad Ziekenhuis
Rotterdam, Netherlands
-
Martini Ziekenhuis
Groningen, Netherlands
-
Meander Medisch Centrum
Amersfoort, Netherlands
-
Medisch Centrum Leeuwarden
Leeuwarden, Netherlands
-
Medisch Spectrum Twente
Enschede, Netherlands
-
Máxima Medisch Centrum
Eindhoven, Netherlands
-
Noordwest Ziekenhuisgroep
Alkmaar, Netherlands
-
Reinier de Graaf Gasthuis
Delft, Netherlands
-
Rijnstate
Arnhem, Netherlands
-
Spaarne Gasthuis
Hoofddorp, Netherlands
-
St. Antonius Ziekenhuis
Nieuwegein, Netherlands
-
VieCuri Medisch Centrum
Venlo, Netherlands
-
Ziekenhuis Amstelland
Amstelveen, Netherlands
-
Ziekenhuisgroep Twente
Almelo, Netherlands